Feldman Ted, Glower Donald
Cardiac Catheterization Laboratory at Evanston Northwestern Healthcare, and Northwestern University Medical School, Evanston, IL, USA.
Nat Clin Pract Cardiovasc Med. 2008 Feb;5(2):84-90. doi: 10.1038/ncpcardio1068.
Surgical valve repair for mitral regurgitation (MR) has been used for decades. Percutaneous approaches to mitral valve repair have been undergoing evaluation in trials over the last few years, and could offer less-invasive alternatives to surgery for the treatment of MR. Patient selection for surgical repair has been defined not only by the pathophysiology of MR, but also by the likelihood of successful repair for degenerative compared with functional MR. Patients with degenerative MR have excellent acute and long-term results following surgical repair; the acute risks of surgery in patients with heart failure are high in comparison, and late recurrent MR has been problematic after surgical repair for ischemic MR. Patient selection for percutaneous approaches to MR will be influenced by both the underlying valve pathology and the expected outcomes in various patient subsets, and also by the characteristics of the various percutaneous devices. This Review examines the established selection criteria for surgical repair and discusses the potential impact of new percutaneous approaches.
二尖瓣反流(MR)的外科瓣膜修复术已应用数十年。在过去几年中,经皮二尖瓣修复方法一直在试验中接受评估,可为MR治疗提供侵入性较小的手术替代方案。外科修复的患者选择不仅取决于MR的病理生理学,还取决于退行性MR与功能性MR相比成功修复的可能性。退行性MR患者在外科修复后具有出色的急性和长期效果;相比之下,心力衰竭患者手术的急性风险较高,缺血性MR外科修复后的晚期复发性MR一直是个问题。经皮MR方法的患者选择将受到潜在瓣膜病理、不同患者亚组的预期结果以及各种经皮装置特性的影响。本综述探讨了外科修复既定的选择标准,并讨论了新的经皮方法的潜在影响。